• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Health

UCLA Health
  • About Us
    • What is UCLA Health?
    • Contact Us
    • Your Feedback
    • Accountable Care Organization
    • Awards & Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • In the Community
    • 340B Program
    • Industry Relations
    • Innovation
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    Vital SignsLinked Graphic: Subscribe to Health Newsletters
    • Contact
    • Your Feedback
    • Accountable Care Organization
    • Awards and Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Industry Relations
    • Innovation
    • In the Community
    • 340B Program
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • Subscribe to UCLA Health Newsletters
  • Conditions & Treatment
    • Health Library
    • Tests & Procedures
    • Drug Interaction Checker
    • Brain & Nervous System
    • Cancer
    • Children's Health
    • Heart Disease
    • Nutrition & Wellness
    • Pregnancy & Newborns
    • Orthopedics
    • Women's Health
    • Video Library
    • Cancer
    • Cardiovascular
    • Chiropractic
    • Cosmetic Surgery
    • Ear, Nose and Throat
    • Gastrointestinal
    • General Healthcare
    • Neurological
    • Obstetrics/Gynecology
    • See all videos...
    Symptom Checker
    • Video Library
  • Locations

    Hospitals

    • Ronald Reagan UCLA Medical Center
    • UCLA Medical Center, Santa Monica
    • UCLA Mattel Children's Hospital
    • Resnick Neuropsychiatric Hospital
    • Institutes and Centers
    • Take a Virtual Tour

    Medical Offices/Clinics

    • Primary Care
    • Specialty Care
    • Immediate Care
    • Emergency Care
    • Outpatient Surgery Centers
    • Community Cancer Care
    • Pediatric Locations
    • Imaging/Radiology
    • Clinical Labs
    • Pharmacies

    Interactive Map

    interactive map

    • Locations Coming Soon
    • UCLA Hospitals
    • Take a Virtual Tour
    • Primary Care Practices
    • Specialty Care Practices
    • Immediate Care
    • Emergency Care
    • Pediatric Locations
    • Outpatient Surgery Centers
    • Other Locations
    • Interactive Map
    • Coming Soon!
  • Medical Services
  • For Patients & Visitors
    • Directions & Parking
    • Appointments: Call, Click, Come In
    • Admissions
    • Preparing For Surgery
    • Patient Services
    • Security & Parking Services
    • Office of the Patient Experience
    • For International Patients
    • Lodging & Nearby Services
    • Around Westwood
    • Gift Shops & Flowers
    • Patient Greeting Cards
    • Log in to myUCLAhealth
    • Billing and Insurance
    • Medical Records
    • Accountable Care Organization (ACO)
    • Price Transparency
    • Interactive Patient Education Videos (Emmi)
    • FAQs
    • Calendar of Events
    • Secure Email Messages
    • Health Resources
    • Share your story. Connect. Share. Improve. UCLA Health
    • Share Your Story
    • Send a Care Compliment
    • Health Publications
    • Vital Signs Newsletters
    • Health Tips for Parents
    • Contact Us
    • Appointments: Call, Click, Come in
    • Admissions Information
    • Advance Directive
    • Directions & Parking
    • Patient Services
    • Medical Records
    • myUCLAhealth
    • Smoke-Free
    • Publications
    • Health Resources
    • Around Westwood
    • Lodging
    • Preparing For Surgery
    • Patient-focused Technology Council
    • Health Forms
    • End of Life Option Act: Resources & Materials
    • Frequently Asked Questions
    • Secure Email Messages
    • Gift Shops
  • For Healthcare Professionals
    • Referring a Patient
    • Continuing Medical Education
    • Ethics Center
    • UCLA HealthLink
    • Physician to Physician Access Line (P2P)
    • David Geffen School of Medicine at UCLA
    • Clinical Informatics Fellowship
    • Academic Positions
    • Physician Careers
    • UCLA School of Dentistry
    • UCLA School of Nursing
    • Department of Nursing

    Physician Publications

    • Physicians Update
    • Clinical Updates
    • U Magazine
    • Physician to Physician Access Line (P2P)
    • Physician Careers
    • Clinical Informatics Fellowship
    • Flu Resources for Healthcare Professionals
    • Publications
  • Multimedia
    • UCLAMDCHAT Webinars
    • Community Health Program Videos
    • Closer to a Cure LLS Series
    • iTunes
    • Download Our Apps
    • Mini Med School
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips from our Physical Therapists
    • Patient Stories
    • Real Questions
    • Webinars on Demand
    • Pediatric Grand Rounds
    • Tune in to watch our health webinars
    • Community Health Program Videos
    • UCLAMDChat Webinars
    • iTunes
    • Download Our Apps
    • UCLA Health Zone Radio and Podcast
    • Mini Med School
    • Closer to A Cure
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips From Our Physical Therapists
    • Patient Stories
    • Real Questions
    • Back Pain Management
  • Find a Provider
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

News Releases

  1. Home
  2. About Us
  3. News Releases

News Releases

Health and Behavior

FDA approves new drug to treat estrogen-receptor–positive breast cancer

02/03/2015

The U.S. Food and Drug Administration today approved a new drug to treat patients with advanced breast cancer, signaling a new strategy for arresting tumor growth and extending the time before cancer worsens in women with metastatic disease.

The drug, Ibrance (palbociclib), was studied in 165 post-menopausal women with advanced estrogen–receptor positive (ER+) and HER2–negative (HER2-) breast cancer who had received no prior systemic therapy for their metastatic disease. In 2013, after patients in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted the drug "breakthrough therapy" status, allowing it to be fast-tracked for approval.

ER+/HER2- is the most common type of breast cancer; it is traditionally treated with therapies like tamoxifen or letrozole that target the hormone receptor pathway.

"Ibrance is the first drug in its class to be approved by the FDA," said Dr. Richard Finn, the study's principal investigator and a researcher at UCLA's Jonsson Comprehensive Cancer Center. "All of us at UCLA are very proud of the important role we played in bringing this new agent to patients."

Developed by Pfizer, Ibrance targets proteins in cancer cells — cyclin D kinase 4 (CDK 4) and cyclin D kinase 6 (CDK 6) — preventing the cells from dividing. A multiyear phase 2 study found a significantly higher progression-free survival rate for patients with advanced ER+/HER2- breast cancer who were given palbociclib in addition to letrozole, a standard anti-estrogen treatment, compared with women who received letrozole alone.

"With the FDA approval, this study represents a potential practice-changing result," said Dr. Dennis Slamon, director of the Revlon/UCLA Women's Cancer Research Program and director of clinical and translational research at the Jonsson Cancer Center. "I believe palbociclib will now become a standard treatment approach for postmenopausal women with ER+/HER2- metastatic breast cancer."

Developing Ibrance

The research originated in 2007, when Finn and Slamon met with Pfizer to discuss palbociclib and other experimental drugs in the company's pipeline.

In preclinical trials, the drug showed encouraging results against human breast cancer cells in culture dishes — and specifically against ER+ cancer cells. This led to a clinical study collaboration with Pfizer led by Finn and Slamon built on work at the Jonsson Cancer Center's Translational Oncology Research Laboratory.

A phase 2 study evaluated the drug in 165 post-menopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic therapy for their metastatic disease. It showed progression-free survival was 20.2 months for patients who received palbociclib plus letrozole, compared with 10.2 months for those who received the letrozole alone. The results also indicated a 51 percent reduction in the risk of disease progression when palbociclib was used with letrozole.

"What is really remarkable is that we doubled the median progression-free survival," Finn said. "That type of result is not often seen in cancer medicine."

Over 80 percent of the women in the study with metastatic ER+ breast cancer received some benefit from the treatment. The drug's safety profile is distinct from traditional chemotherapy, but it does result in a lowered white blood cell count, which is manageable.

A phase 3 international clinical trial of the drug conducted by Finn and Slamon with Pfizer in approximately 660 people with advanced ER+/HER2- breast cancer has been completely enrolled.

Survivor stories

Janet Klein was first diagnosed with stage 1 ER+ breast cancer in 2004, and she decided to undergo a double mastectomy. A few years later, doctors discovered that the breast cancer had returned as metastatic disease in her bones.

Dr. Sara Hurvitz, a UCLA oncologist and member of the Jonsson Cancer Center, told Klein about the clinical trial at UCLA. Klein enrolled and was prescribed Ibrance in combination with an anti-estrogen treatment. Nine months later, her scans showed no evidence of the cancer.

"I had a large party with a lot of champagne," she said. "It was life-changing but in a good way." said Klein.

Klein, now 59, said the FDA approval was cause for more celebration. "Sixty percent of all women diagnosed with this disease have my variety, and this drug having this sort of an impact, so fast and so effectively, is earth shattering."

Gloria Zollar, 78, joined the phase 2 clinical trial in 2010 after her UCLA oncologist discovered that her advanced breast cancer had spread to her bones. She has been on treatment since that then.

But after only a year of treatment, doctors noticed that Zollar's tumors had stopped progressing — allowing her to remain active and continue playing golf.

"I am now in remission, and every day I'm thankful to God that I'm alive and able to see my great-grandchildren and spend time with them," Zollar said.

She also is excited that the drug is now available to other women. "I am very pleased that other women could have a second chance at life like many of us who participated in the trial," Zollar said.



Media Contact
Reggie Kumar
310-267-7022
UCLAHealthNews@mednet.ucla.edu



Latest News

Health and Behavior
ER visits did not rise with Medicaid expansion under Affordable Care Act
12/12/2019
Research brief: The findings also show that patient visits by Medicaid recipients to primary care physicians rose 3.6% during the first three years of the act.

Health and Behavior
Targeted therapy drug helps women with aggressive breast cancer live longer
12/11/2019
The drug combination should be a first line of treatment, UCLA researchers say.

Health and Behavior
Father's X chromosome may yield clues to higher rates of autoimmune disease in women
12/10/2019
UCLA researchers discovered differences in maternal and paternal X chromosomes that help explain sex differences in the immune system.

Health and Behavior
Researchers create accurate model of organ scarring using stem cells in a lab
12/10/2019
The advance could help scientists identify drugs to treat fibrosis, which plays a role in chronic kidney disease, liver cirrhosis and many other conditions.

Health and Behavior
UCLA study shows inhibition of gene helps overcome resistance to immunotherapy
12/09/2019
A combination approach could be new strategy for people with advanced cancers.

Facebook Twitter Instagram Youtube LinkedIn
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-800-UCLA-MD1
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap

Sign in to myUCLAhealth